Which response indicates a diagnosis of myasthenia gravis after Edrophonium administration?

Which response indicates a diagnosis of myasthenia gravis after Edrophonium administration?

• A. An increase in muscle strength within 30 to 60 seconds
• B. Decrease in muscle strength within an hour
• C. Muscle spasms following administration
• D. Severe fatigue after medication

Answer: (A)

A diagnosis of myasthenia gravis can be indicated by an increase in muscle strength shortly after administration of Edrophonium, a short-acting acetylcholinesterase inhibitor. This drug temporarily enhances the availability of acetylcholine at the neuromuscular junction, which often leads to a rapid improvement in muscle strength for patients suffering from myasthenia gravis, where there is a blockade of acetylcholine receptors. The positive response typically occurs within 30 to 60 seconds after Edrophonium is administered, providing a clear diagnostic tool for this condition. The other responses do not align with the expected outcomes for Edrophonium in patients with myasthenia gravis. A decrease in muscle strength, muscle spasms, or severe fatigue would not provide supportive evidence for a diagnosis of myasthenia gravis; rather, they indicate other issues or non-responsiveness to the treatment. The quick increase in muscle strength is a hallmark of the effectiveness of Edrophonium in diagnosing this neurological disorder.

A diagnosis of myasthenia gravis can be indicated by an increase in muscle strength shortly after administration of Edrophonium, a short-acting acetylcholinesterase inhibitor. This drug temporarily enhances the availability of acetylcholine at the neuromuscular junction, which often leads to a rapid improvement in muscle strength for patients suffering from myasthenia gravis, where there is a blockade of acetylcholine receptors. The positive response typically occurs within 30 to 60 seconds after Edrophonium is administered, providing a clear diagnostic tool for this condition.

The other responses do not align with the expected outcomes for Edrophonium in patients with myasthenia gravis. A decrease in muscle strength, muscle spasms, or severe fatigue would not provide supportive evidence for a diagnosis of myasthenia gravis; rather, they indicate other issues or non-responsiveness to the treatment. The quick increase in muscle strength is a hallmark of the effectiveness of Edrophonium in diagnosing this neurological disorder.